Commonly used nonionic surfactants interact differently with the human efflux transporters ABCB1 (p-glycoprotein) and ABCC2 (MRP2).

The efflux transporters ABCB1 (p-glycoprotein) and ABCC2 (MRP2) play an essential role in the limitation of oral bioavailability of drugs. In the last years, pharmaceutical surfactants like cremophor® EL or polysorbate 80 have been shown to interact with ABCB1. However, the knowledge about their influence on ABCC2 is still limited. In this study, the interactions of the nonionic surfactants cremophor® EL, cremophor® RH 40, polysorbate 80, vitamin E TPGS 1000, pluronic® PE 10300 and sucrose ester L-1695 with both efflux transporters were investigated on cellular level. Cell accumulation studies and transport studies were performed using transfected MDCK II cell models. The influence of ABCC2 inhibiting surfactants on the expression level of ABCC2 was also studied. The investigations showed that cremophor® EL, vitamin E TPGS 1000 and higher concentrations of polysorbate 80 inhibit both transporters. Pluronic® PE 10300 and sucrose ester L-1695 inhibit ABCB1 but not ABCC2. Cremophor® RH 40 only shows inhibitory activity on ABCC2. During the investigated incubation period none of the inhibiting surfactants caused an alteration in ABCC2mRNA or protein expression. These findings indicate that the observed interactions are caused by specific inhibition of the transport activity of ABCC2.

[1]  K. Lyons,et al.  Utility of unbound plasma drug levels and P-glycoprotein transport data in prediction of central nervous system exposure , 2009, Xenobiotica; the fate of foreign compounds in biological systems.

[2]  A. Kabanov,et al.  Effect of Pluronic P85 on ATPase Activity of Drug Efflux Transporters , 2004, Pharmaceutical Research.

[3]  D. Aggarwal,et al.  Paclitaxel and its formulations. , 2002, International journal of pharmaceutics.

[4]  M. Schleimer,et al.  Potential inhibitory effects of formulation ingredients on intestinal cytochrome P450. , 2000, International journal of pharmaceutics.

[5]  G. Fricker,et al.  Xenobiotic efflux pumps in isolated fish brain capillaries. , 2002, American journal of physiology. Regulatory, integrative and comparative physiology.

[6]  P. Artursson,et al.  Epithelial transport of drugs in cell culture. I: A model for studying the passive diffusion of drugs over intestinal absorptive (Caco-2) cells. , 1990, Journal of pharmaceutical sciences.

[7]  B. Hirst,et al.  Intestinal secretion of drugs. The role of P-glycoprotein and related drug efflux systems in limiting oral drug absorption , 1997 .

[8]  P. Twentyman,et al.  On the relationship between the probenecid‐sensitive transport of daunorubicin or calcein and the glutathione status of cells overexpressing the multidrug resistance‐associated protein (MRP) , 1995, International journal of cancer.

[9]  D. Stevens,et al.  Effect of cyclodextrin on the pharmacology of antifungal oral azoles , 1992, Antimicrobial Agents and Chemotherapy.

[10]  Yuichi Sugiyama,et al.  Comparative Studies on in Vitro Methods for Evaluating in Vivo Function of MDR1 P-Glycoprotein , 2001, Pharmaceutical Research.

[11]  W. Hauck,et al.  Interpatient variability in bioavailability is related to the extent of absorption: Implications for bioavailability and bioequivalence studies , 1996, Clinical pharmacology and therapeutics.

[12]  Gerd Mikus,et al.  Pharmacokinetic and pharmaceutic interaction between digoxin and Cremophor RH40 , 2003, Clinical pharmacology and therapeutics.

[13]  D. Hallifax,et al.  Predicting P-Glycoprotein Effects on Oral Absorption: Correlation of Transport in Caco-2 with Drug Pharmacokinetics in Wild-Type and mdr1a(-/-) Mice in Vivo , 2004, Pharmaceutical Research.

[14]  T. Zoeller,et al.  Improving glyburide solubility and dissolution by complexation with hydroxybutenyl‐β‐cyclodextrin , 2009 .

[15]  D. Schrenk,et al.  Evaluation of a vincristine resistant Caco-2 cell line for use in a calcein AM extrusion screening assay for P-glycoprotein interaction. , 2001, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[16]  J. Schellens,et al.  Evidence for Two Interacting Ligand Binding Sites in Human Multidrug Resistance Protein 2 (ATP Binding Cassette C2)* , 2003, Journal of Biological Chemistry.

[17]  B. Tran,et al.  Probenecid reverses multidrug resistance in multidrug resistance-associated protein-overexpressing HL60/AR and H69/AR cells but not in P-glycoprotein-overexpressing HL60/Tax and P388/ADR cells , 1997, Cancer Chemotherapy and Pharmacology.

[18]  B. Hirst,et al.  The ABCs of drug transport in intestine and liver: efflux proteins limiting drug absorption and bioavailability. , 2004, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[19]  M C Willingham,et al.  Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[20]  M. Kool,et al.  Inhibitory effect of the reversal agents V-104, GF120918 and Pluronic L61 on MDR1 Pgp-, MRP1- and MRP2-mediated transport , 2000, British Journal of Cancer.

[21]  R L Juliano,et al.  A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. , 1976, Biochimica et biophysica acta.

[22]  C. Higgins,et al.  ABC transporters: from microorganisms to man. , 1992, Annual review of cell biology.

[23]  M. Wempe,et al.  Influence of vitamin E TPGS poly(ethylene glycol) chain length on apical efflux transporters in Caco-2 cell monolayers. , 2006, Journal of controlled release : official journal of the Controlled Release Society.

[24]  B. Williams,et al.  Reversal of the multidrug resistance phenotype with cremophor EL, a common vehicle for water-insoluble vitamins and drugs. , 1990, Cancer research.

[25]  K. Anderson,et al.  Reversal of multidrug resistance phenotype by surfactants: relationship to membrane lipid fluidity. , 1995, Archives of biochemistry and biophysics.

[26]  M. Gottesman,et al.  Targeting multidrug resistance in cancer , 2006, Nature Reviews Drug Discovery.

[27]  B. Aungst,et al.  Intestinal permeation enhancers. , 2000, Journal of pharmaceutical sciences.

[28]  J. Huwyler,et al.  Improved oral bioavailability of cyclosporin A in male Wistar rats. Comparison of a Solutol HS 15 containing self-dispersing formulation and a microsuspension. , 2002, International journal of pharmaceutics.

[29]  M. Kool,et al.  Drug export activity of the human canalicular multispecific organic anion transporter in polarized kidney MDCK cells expressing cMOAT (MRP2) cDNA. , 1998, The Journal of clinical investigation.

[30]  Alexander V Kabanov,et al.  Optimal Structure Requirements for Pluronic Block Copolymers in Modifying P-glycoprotein Drug Efflux Transporter Activity in Bovine Brain Microvessel Endothelial Cells , 2003, Journal of Pharmacology and Experimental Therapeutics.

[31]  F. Russel,et al.  Impaired renal secretion of substrates for the multidrug resistance protein 2 in mutant transport-deficient (TR-) rats. , 2003, Journal of the American Society of Nephrology : JASN.

[32]  P. Bosma,et al.  Congenital Jaundice in Rats with a Mutation in a Multidrug Resistance-Associated Protein Gene , 1996, Science.

[33]  C. Klaassen,et al.  Organ distribution of multidrug resistance proteins 1, 2, and 3 (Mrp1, 2, and 3) mRNA and hepatic induction of Mrp3 by constitutive androstane receptor activators in rats. , 2002, The Journal of pharmacology and experimental therapeutics.

[34]  D. Keppler,et al.  The rat canalicular conjugate export pump (Mrp2) is down-regulated in intrahepatic and obstructive cholestasis. , 1997, Gastroenterology.

[35]  Yuichi Sugiyama,et al.  Improvement of the Oral Drug Absorption of Topotecan through the Inhibition of Intestinal Xenobiotic Efflux Transporter, Breast Cancer Resistance Protein, by Excipients , 2007, Drug Metabolism and Disposition.

[36]  R. Borchardt,et al.  The Use of Surfactants to Enhance the Permeability of Peptides Through Caco-2 Cells by Inhibition of an Apically Polarized Efflux System , 1996, Pharmaceutical Research.

[37]  I. Wilson,et al.  Investigation of the Alamar Blue (resazurin) fluorescent dye for the assessment of mammalian cell cytotoxicity. , 2000, European journal of biochemistry.

[38]  Akira Yamamoto,et al.  Modulation of intestinal P-glycoprotein function by cremophor EL and other surfactants by an in vitro diffusion chamber method using the isolated rat intestinal membranes. , 2004, Journal of pharmaceutical sciences.

[39]  P. Borst,et al.  Absence of the mdr1a P-Glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A. , 1995, The Journal of clinical investigation.

[40]  James E Polli,et al.  Effects of nonionic surfactants on membrane transporters in Caco-2 cell monolayers. , 2002, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[41]  N. Shaik,et al.  Investigation of the micellar effect of pluronic P85 on P-glycoprotein inhibition: cell accumulation and equilibrium dialysis studies. , 2009, Journal of Pharmacy and Science.

[42]  Donald W. Miller,et al.  Sensitization of Cells Overexpressing Multidrug-Resistant Proteins by Pluronic P85 , 2003, Pharmaceutical Research.

[43]  D. Häussinger,et al.  Regulation of the multidrug resistance protein 2 in the rat liver by lipopolysaccharide and dexamethasone. , 1999, Gastroenterology.

[44]  Jochem Alsenz,et al.  The role of surfactants in the reversal of active transport mediated by multidrug resistance proteins. , 2003, Journal of pharmaceutical sciences.

[45]  G. Fricker,et al.  Relevance of multidrug resistance proteins for intestinal drug absorption in vitro and in vivo. , 2002, Pharmacology & toxicology.

[46]  J. Verweij,et al.  Rapid esterase-sensitive breakdown of polysorbate 80 and its impact on the plasma pharmacokinetics of docetaxel and metabolites in mice. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[47]  A. Collett,et al.  Investigation of Regional Mechanisms Responsible for Poor Oral Absorption in Humans of a Modified Release Preparation of the α-Adrenoreceptor Antagonist, 4-Amino-6,7-dimethoxy-2-(5-methanesulfonamido-1,2,3,4 tetrahydroisoquinol-2-yl)-5-(2-pyridyl)quinazoline (UK-338,003): The Rational Use of ex Vivo , 2008, Drug Metabolism and Disposition.